Cancer immunotherapies may be improved with early immune response
A new mechanism has been reported for detecting foreign material during early immune responses which may help detect elusive cancers.
List view / Grid view
Oncology is a branch of medicine that deals with the prevention, diagnosis and treatment of cancer.
A new mechanism has been reported for detecting foreign material during early immune responses which may help detect elusive cancers.
Researchers have found that the TRAP-alpha insulin biosynthesis pathway is essential in both cancer and diabetes, with a common primordial ancestor discovered in C. elegans.
The new screening technique may enable development of novel combination-immunotherapy regimens against cancers and persistent infections.
A study conducted on human pancreatic tumours transplanted in mice reveals promise for an effective therapy in the future, say researchers.
A study has demonstrated how mutations in early colon cancer prevail and grow into malignancies, using fluorescent imaging.
A new study into the molecular causes of acute lymphoblastic leukaemia could lead to a new target for therapy.
A new discovery that healthy liver tissue surrounding a tumour activates a defence mechanism that restrains tumour growth could inspire new therapeutic approaches that mobilise normal cells to kill cancer cells.
A new signalling pathway has been identified that may help further the understanding of blood clot formation in cancer patients and presents a new drug target for reducing cancer-associated complications.
Researchers have discovered a potential new strategy for treating myelodysplastic syndrome, which has shown to be successful in pre-clinical trials.
Researchers have created a new high-throughput screening system which could identify new drugs by focusing on nucleotide metabolism.
A pioneering team of scientists from Rice University has discovered that a particular combination of chemotherapeutics, including mitocans that target mitochondria, form a powerful treatment for acute myeloid leukaemia patients.
The involvement of clathrin in the development of liver cancer has been described for the first time, which could lead to more targeted therapy.
A novel CDK8 inhibitor has been developed by scientists at Ryvu Therapeutics. Dr Krzysztof Brzozka showcases this molecule and explains the R&D behind it.
A team has imaged the process that the body uses to stabilise DNA, which could be used to develop therapies for conditions such as cancer.
A new study has shown the specific cellular mechanisms that limit the ability of CD8 T cells to infiltrate the tumour microenvironment, which could guide new immunotherapeutic strategies in cancer.